An overview of canine histiocytic disorders

Rebecca E. Risbon, Craig A. Clifford, Katherine A Skorupski

Research output: Contribution to journalArticle

Abstract

The canine histiocytic diseases represent a complex of diseases originating from myeloid dendritic cells.3 Although originating from a common precursor, the benign and malignant counterparts of the histiocytic disease spectrum are vastly different in biologic behavior, recommended treatment, and prognosis. Recognizing the breed and age predilections for this spectrum of clinical diseases is paramount to identifying cases that require a diagnostic workup. Immunohistochemical analysis is beneficial in solidifying an accurate diagnosis so that appropriate therapy can be instituted promptly, as aggressive early treatment can improve survival times in dogs with histiocytic sarcoma. Recent retrospective analyses have shown promise for combination therapy, including radiation therapy and chemotherapy to treat histiocytic sarcoma. Controlled, prospective studies are warranted to determine the appropriate treatment of histiocytic sarcoma.

Original languageEnglish (US)
Pages (from-to)464-480
Number of pages17
JournalVeterinary Medicine
Volume102
Issue number7
StatePublished - Jul 2007

Fingerprint

sarcoma
Canidae
Histiocytic Sarcoma
dogs
therapeutics
dog diseases
radiotherapy
prospective studies
prognosis
drug therapy
Dog Diseases
Therapeutics
breeds
Radiotherapy
Prospective Studies
Dogs
Drug Therapy

ASJC Scopus subject areas

  • Small Animals

Cite this

Risbon, R. E., Clifford, C. A., & Skorupski, K. A. (2007). An overview of canine histiocytic disorders. Veterinary Medicine, 102(7), 464-480.

An overview of canine histiocytic disorders. / Risbon, Rebecca E.; Clifford, Craig A.; Skorupski, Katherine A.

In: Veterinary Medicine, Vol. 102, No. 7, 07.2007, p. 464-480.

Research output: Contribution to journalArticle

Risbon, RE, Clifford, CA & Skorupski, KA 2007, 'An overview of canine histiocytic disorders', Veterinary Medicine, vol. 102, no. 7, pp. 464-480.
Risbon RE, Clifford CA, Skorupski KA. An overview of canine histiocytic disorders. Veterinary Medicine. 2007 Jul;102(7):464-480.
Risbon, Rebecca E. ; Clifford, Craig A. ; Skorupski, Katherine A. / An overview of canine histiocytic disorders. In: Veterinary Medicine. 2007 ; Vol. 102, No. 7. pp. 464-480.
@article{2877d5a4f1ca44acbe5aab25d3b2d373,
title = "An overview of canine histiocytic disorders",
abstract = "The canine histiocytic diseases represent a complex of diseases originating from myeloid dendritic cells.3 Although originating from a common precursor, the benign and malignant counterparts of the histiocytic disease spectrum are vastly different in biologic behavior, recommended treatment, and prognosis. Recognizing the breed and age predilections for this spectrum of clinical diseases is paramount to identifying cases that require a diagnostic workup. Immunohistochemical analysis is beneficial in solidifying an accurate diagnosis so that appropriate therapy can be instituted promptly, as aggressive early treatment can improve survival times in dogs with histiocytic sarcoma. Recent retrospective analyses have shown promise for combination therapy, including radiation therapy and chemotherapy to treat histiocytic sarcoma. Controlled, prospective studies are warranted to determine the appropriate treatment of histiocytic sarcoma.",
author = "Risbon, {Rebecca E.} and Clifford, {Craig A.} and Skorupski, {Katherine A}",
year = "2007",
month = "7",
language = "English (US)",
volume = "102",
pages = "464--480",
journal = "Veterinary medicine, small animal clinician : VM, SAC",
issn = "8750-7943",
publisher = "Advanstar Communications",
number = "7",

}

TY - JOUR

T1 - An overview of canine histiocytic disorders

AU - Risbon, Rebecca E.

AU - Clifford, Craig A.

AU - Skorupski, Katherine A

PY - 2007/7

Y1 - 2007/7

N2 - The canine histiocytic diseases represent a complex of diseases originating from myeloid dendritic cells.3 Although originating from a common precursor, the benign and malignant counterparts of the histiocytic disease spectrum are vastly different in biologic behavior, recommended treatment, and prognosis. Recognizing the breed and age predilections for this spectrum of clinical diseases is paramount to identifying cases that require a diagnostic workup. Immunohistochemical analysis is beneficial in solidifying an accurate diagnosis so that appropriate therapy can be instituted promptly, as aggressive early treatment can improve survival times in dogs with histiocytic sarcoma. Recent retrospective analyses have shown promise for combination therapy, including radiation therapy and chemotherapy to treat histiocytic sarcoma. Controlled, prospective studies are warranted to determine the appropriate treatment of histiocytic sarcoma.

AB - The canine histiocytic diseases represent a complex of diseases originating from myeloid dendritic cells.3 Although originating from a common precursor, the benign and malignant counterparts of the histiocytic disease spectrum are vastly different in biologic behavior, recommended treatment, and prognosis. Recognizing the breed and age predilections for this spectrum of clinical diseases is paramount to identifying cases that require a diagnostic workup. Immunohistochemical analysis is beneficial in solidifying an accurate diagnosis so that appropriate therapy can be instituted promptly, as aggressive early treatment can improve survival times in dogs with histiocytic sarcoma. Recent retrospective analyses have shown promise for combination therapy, including radiation therapy and chemotherapy to treat histiocytic sarcoma. Controlled, prospective studies are warranted to determine the appropriate treatment of histiocytic sarcoma.

UR - http://www.scopus.com/inward/record.url?scp=77649174566&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77649174566&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:77649174566

VL - 102

SP - 464

EP - 480

JO - Veterinary medicine, small animal clinician : VM, SAC

JF - Veterinary medicine, small animal clinician : VM, SAC

SN - 8750-7943

IS - 7

ER -